共 33 条
[1]
Schmid P(2018)Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer N Engl J Med 379 2108-2121
[2]
Schmid P(2020)Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 21 44-59
[3]
Emens LA(2019)Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study JAMA Oncol 5 74-82
[4]
Adams S(2017)Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A J Clin Oncol 35 abstr1008-424
[5]
Schmid P(2019)Current challenges in cancer immunotherapy: multimodal approaches to improve efficacy and patient response rates J Oncol 2019 4508794-264
[6]
Rugo HS(2017)Liver metastasis and treatment outcome with anti-PD-1 Monoclonal antibody in patients with melanoma and NSCLC Cancer Immunol Res 5 417-110
[7]
Sambi M(2021)Prevalence study of PD-L1 SP142 assay in metastatic triple-negative breast cancer Appl Immunohistochem Mol Morphol 29 258-103681
[8]
Bagheri L(2016)Immunology in the liver–from homeostasis to disease Nat Rev Gastroenterol Hepatol 13 88-993
[9]
Szewczuk MR(2017)Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer Oncotarget 8 103671-404
[10]
Tumeh PC(2021)First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis Ann Oncol 32 983-5464